Pasithea Therapeutics Corp. (KTTAW) Change in Accured Expenses (2021 - 2026)

Pasithea Therapeutics has disclosed Change in Accured Expenses across 6 years of filings, most recently posting $348432.0 for Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 36.33% year-over-year to $348432.0; the TTM figure through Jun 2026 stood at $256416.0 (up 37.38% YoY), while the FY2025 annual figure was $11233.0, up 100.78% from the prior year.
• Change in Accured Expenses came in at $348432.0 for Q2 2026 at Pasithea Therapeutics, down from $358381.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $682903.0 in Q4 2023 to a low of -$1.0 million in Q2 2024.
• Average Change in Accured Expenses over 5 years is $61237.9, with a median of $118219.0 recorded in 2022.
• Year-over-year, Change in Accured Expenses jumped 1437.84% in 2023 and slumped 1572.63% in 2024.
• Over 5 years, Change in Accured Expenses stood at $280153.0 in 2022, then jumped by 143.76% to $682903.0 in 2023, then retreated by 29.22% to $483373.0 in 2024, then slumped by 142.76% to -$206697.0 in 2025, then soared by 268.57% to $348432.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $348432.0 in Q2 2026, $358381.0 in Q1 2026, and -$206697.0 in Q4 2025.